SCHEMBL353360

SCHEMBL353360

CNC(=O)c1cnn(C)c1C(F)(F)F

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 2/20 0.46
AXL P30530 1/20 0.46
ALDH1A1 P00352 3/20 0.43
KDM4E B2RXH2 2/20 0.43
SSTR2 P30874 1/20 0.41
KCNH2 Q12809 1/20 0.41
MAPT P10636 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
POLB P06746 1/20 0.39
MGLL Q99685 1/20 0.38
RAB9A P51151 2/20 0.37
CYP11B2 P19099 1/20 0.37
MALT1 Q9UDY8 3/20 0.37
KMT2A Q03164 1/20 0.37
BAZ2B Q9UIF8 1/20 0.37
HTR1A P08908 1/20 0.36
HTR1D P28221 1/20 0.36
HTR1B P28222 1/20 0.36
IRAK4 Q9NWZ3 1/20 0.36
NPC1 O15118 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15354814 0.83 TRPC3 (0.50) METAXLALDH1A1KDM4ESSTR2
SCHEMBL1196081 0.81 POLB (0.57) METAXLALDH1A1KDM4EMAPT
SCHEMBL10365011 0.81 TRPA1 (0.48) METALDH1A1KDM4EMAPTSMN1; SMN2
SCHEMBL2322890 0.80 MET (0.43) METAXLALDH1A1KDM4ESSTR2
SCHEMBL939312 0.79 MAPT (0.41) METAXLALDH1A1KDM4ESSTR2
SCHEMBL353368 0.79 POLB (0.41) METAXLALDH1A1KDM4ESSTR2
SCHEMBL23626145 0.77 HSD11B1 (0.57) ALDH1A1KDM4EMAPTSMN1; SMN2POLB
SCHEMBL20683253 0.77 KEAP1 (0.43) METAXLALDH1A1KDM4ESSTR2
SCHEMBL10367084 0.76 ALDH1A1 (0.76) METAXLALDH1A1KDM4EMAPT
SCHEMBL1406622 0.76 HSD11B1 (0.62) ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2426108-B1 Processes and intermediates for preparing fused heterocyclic kinase inhibitors METHYLGENE INC (CA) 2016-08-10 EP disclosed
US-9018378-B2 Processes and intermediates for preparing fused heterocyclic kinase inhibitors METHYLGENE INC. (CA) 2015-04-28 US disclosed
US-8846927-B2 Inhibitors of protein tyrosine kinase activity METHYLGENE INC. (CA) 2014-09-30 US disclosed
US-8569503-B2 Processes and intermediates for preparing fused heterocyclic kinase inhibitors METHYLGENE INC. (CA) 2013-10-29 US disclosed
US-20130165477-A1 INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY METHYLGENE INC. (CA) 2013-06-27 US disclosed
US-8377923-B2 Triazole derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2013-02-19 US disclosed
US-8148380-B2 Antibacterial amide and sulfonamide substituted heterocyclic urea compounds CRESTONE, INC. (US) 2012-04-03 US disclosed
US-20120015941-A1 Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds CRESTONE, INC. (US) 2012-01-19 US disclosed
US-20110105460-A1 TRIAZOLE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2011-05-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165477-A1 INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY HGF, ERBB2, MET MET 3/4885AXL 130/4885ALDH1A1 3139/4885
US-20120015941-A1 Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds NAAA, AADAC, RPSA MET 4089/4885AXL 1229/4885ALDH1A1 2806/4885
US-20110105460-A1 TRIAZOLE DERIVATIVE OR SALT THEREOF HSD11B1, HSD11B2, HSD3B1 MET 2975/4885AXL 4823/4885ALDH1A1 359/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.